1.Clinical efficacy and safety of clearing liver -fire traditional Chinese medicine therapy in the treatment of single blister viral keratitis
Di-Hua WENG ; Jing SHI ; Xin-Rong HE
The Chinese Journal of Clinical Pharmacology 2015;(16):1582-1584
Objective To explore the clinical efficacy of traditional Chi-nese medicine therapy in the treatment of single blister viral keratitis. Methods One hundred twelve patients of single blister viral keratitis were randomly divided into control group ( n=52 , 80 eyes ) and treat-ment group ( n=60, 83 eyes).Patients in control group were given acy-clovir eye drops, each times was 0.05 mL bid, a period of treatment was 0.5 mL with 2 to 3 periods.Patients in treatment group were given clear-ing liver-fire traditional Chinese medicine therapy, 1 day 1 agent, 3 times with boiling form, the first and second oral, third smoked eyes, a period of treatment was 5 agents with 2 to 3 periods.Comparison of the clinical efficacy, vision and incidence of adverse drug reactions in two groups was performed.Results Total effective rate in treatment group was significantly higher than that in control group (98.79%vs 82.50%, P<0.05).After treatment, the vision was better than control group with statistically significant (P<0.05).The incidence of adverse drug reac-tions were not significantly different between two groups ( P >0.05 ) . Conclusion Clearing liver -fire traditional Chinese medicine therapy can improve the clinical efficacy without increasing the adverse drug reac-tions in the treatment of single blister viral keratitis.
2.Clinical analysis of 36 cases of esophageal mucoepidermoid carcinoma.
Shao-bin CHEN ; Jie-sheng YANG ; Wei-ping YANG ; Hong-rui WENG ; Hua LI ; Di-tian LIU ; Yu-ping CHEN
Chinese Journal of Oncology 2012;34(3):232-235
OBJECTIVETo review the clinical characteristics, diagnosis, treatment and prognosis of esophageal mucoepidermoid carcinoma (MEC).
METHODSClinical data of 36 patients with pathologically confirmed esophageal MEC who received surgical treatment in Cancer Hospital of Shantou University Medical College from Jan 1991 to Jun 2010 were retrospectively analyzed. The survival analysis was performed using Kaplan-Meier method.
RESULTSOf the 4253 patients diagnosed as esophageal cancer during the same time in our center, only 36 had esophageal MEC, accounted for 0.8%. This group included 27 men and 9 women ranging in age from 40 to 78 years (median 58 years). Esophageal MEC showed similar clinical symptoms, radiological and endoscopic features to esophageal squamous cell carcinoma (ESCC). Of the 20 cases who received preoperatively endoscopic biopsy, 18 were misdiagnosed as ESCC and 2 were misdiagnosed as esophageal adenosquamous carcinoma. The mean follow-up duration of this series was 38.8 months (3-142 months). 22 patients died of the disease during the follow-up period, 12 were still alive and 2 were lost of follow-up. The median survival time (MST) of the 36 patients was 29.0 months, and the 1-, 2-, 3-, and 5-year overall survival rates (OS) were 80.6%, 57.1%, 34.4%, 25.8%, respectively.
CONCLUSIONSEsophageal MEC is a rare disease and prone to be misdiagnosed by endoscopic biopsy. Surgical resection is the primary treatment but the prognosis is poor.
Adult ; Aged ; Biopsy ; Carcinoma, Adenosquamous ; pathology ; Carcinoma, Mucoepidermoid ; pathology ; radiotherapy ; surgery ; Carcinoma, Squamous Cell ; pathology ; Diagnostic Errors ; Esophageal Neoplasms ; pathology ; radiotherapy ; surgery ; Esophagectomy ; methods ; Esophagoscopy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Rate
3.Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction.
Zhi-hua TAO ; Xiao-lu MAO ; Cai-hong WANG ; Xiao-dong CHEN ; Kai-yuan YU ; Zhi-liang WENG ; Yuan-ping HU ; Xiao-hua ZHANG ; Hui XIE ; Ou-chen WANG ; Qi-tong SONG ; Cheng-di LI ; Zhan-guo CHEN
National Journal of Andrology 2007;13(2):130-133
OBJECTIVETo analyze the expression of DD3 mRNA in the prostate tissues.
METHODSDD3 mRNA was detected by realtime fluorescent quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR) based on the Taqman technique in the tissues of 27 patients with non-prostate cancer( NPCa), 21 prostate cancer( PCa), 39 benign prostatic hyperplasia (BPH) and 15 normal prostate (NP). The ROC curve was used to evaluate the diagnostic value of DD3 mRNA.
RESULTSDD3 mRNA expression was not detected in the NPCa tissues. The median expressions of DD3 mRNA in PCa, BPH and NP tissues were 7. 2 x 10(6), 2. 5 x 10(4) and 1.5 x 10(4) copies/mg tissue, respectively. The DD3 mRNA expression levels were significantly different between nonmalignant and malignant tissues (P < 0.01). No significant differences in DD3 mRNA expression were detected between the NP and BPH tissues and no significant correlation was found between the DD3 mRNA expression and clinical pathological parameters. The AUC-ROC was 0.937 (95% CI: 0.879 - 0.995) at cutoff value 1.4 x 10(5) copies/mg tissue. The sensitivity, specificity, accuracy, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio for DD3 were 90.5%, 85.0%, 86.7%, 76.0%, 94.3%, 6.03 and 0.11 respectively.
CONCLUSIONThe DD3 mRNA expression is confined to prostate tissues and highly upregulated in PCa tissues. It has a potential application value in the early diagnosis of prostate cancer and the follow-up of the patient.
Aged ; Aged, 80 and over ; Antigens, Neoplasm ; biosynthesis ; genetics ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prostatic Hyperplasia ; metabolism ; pathology ; Prostatic Neoplasms ; metabolism ; pathology ; RNA, Messenger ; genetics ; ROC Curve ; Reverse Transcriptase Polymerase Chain Reaction
4.Textual research on "Zhu" in Chinese classical prescriptions.
Jia-Chen ZHAO ; Qian-Qian WENG ; Yue ZHANG ; Wei ZHANG ; Hua-Sheng PENG ; Hong-Jun YANG ; Zhi-Lai ZHAN
China Journal of Chinese Materia Medica 2019;44(23):5248-5255
Through consulting the ancient herbs and medical books,combining with modern literature and field investigation,this paper makes textual research on herbal medicine,and makes textual research on the name,origin,position and changes of collection and processing of the medicinal herbs in Ancient Classical Prescriptions. " Zhu" wasn't distinguished before the Northern and Southern Dynasties,but the efficacy of the techniques recorded in the documents at that time was similar to that of today's Atractylodis Rhizoma.Tao Hongjing put forward the theory of " red and white" in the Northern and Southern Dynasties. " Cangzhu" and " Baizhu" gradually differentiated,but there was no clear distinction between them. Since Song and Yuan Dynasties, " Baizhu" has been respected and classified in the literature. In Ming Dynasty, " Baizhu" was cultivated and differentiated into different quality specifications according to its growth pattern and origin. Maoshan is the genuine production area of " Cangzhu". The quality of wild " Baizhu" produced in Yuqian city is the best. In modern times,the origins of " Cangzhu" and " Baizhu" were defined according to plant taxonomy. " Zhu" before Song Dynasty was close to Atractylodes lancea, " Baishu" had been respected since the Song Dynasty. So when Song people revised the previous literature,they unified " Zhu" into " Baizhu" and used it for later generations. Its safety and effectiveness have been confirmed,and the wild resources of modern atractylodes are scarce. Therefore,it is suggested that when classical famous prescriptions are developed,the prescription recorded as " Baizhu" does not need to be changed in its origin,that is,A. macrocephala at present or can choose the appropriate basis according to the principle of local righteousness.Textual research shows that the origin of " Cangzhu" in the classical prescription should be A. lancea.
Atractylodes/classification*
;
China
;
Drugs, Chinese Herbal
;
Medicine, Chinese Traditional
;
Phytotherapy
;
Plants, Medicinal/classification*
;
Rhizome
5.Textual research on classical prescription of Acorus tatarinowii.
Qian-Qian WENG ; Jia-Chen ZHAO ; Yue ZHANG ; Wei ZHANG ; Hua-Sheng PENG ; Hong-Jun YANG ; Zhi-Lai ZHAN
China Journal of Chinese Materia Medica 2019;44(23):5256-5261
Based on the prescription books of herbs and medical books of all dynasties,this article makes a textual research on the name,origin,position,quality,collection,processing and concocting of Acorus tatarinowii used in the classical prescription,and clarifies the relationship between ancient and modern,so as to provide reference and basis for the development and utilization of the classical famous prescription.According to research,A. tatarinowii has many aliases and is often remembered as " Chang pu" when use as medicine; It has a wide distribution of resources in our country,all over the country have produced and mostly wild,its producing areas there is a trend of migration to the southeast; It is recorded in the ancient books of Chinese herbs that most of its medicinal parts are roots,and to root thin,solid quality,dense,aromatic smell,full taste,chewing less slag of high quality; It is harvested in February,May,August and December,and dried in the shade after harvesting; Its concocting methods are more than 20 species have been recorded; Before the Tang Dynasty,the basis of the medicinal A. tatarinowii was relatively chaotic,through textual research,it is concluded that A. tatarinowii should be the mainstream in all dynasties,and that its quality is superior to that of other species in the same genus.It is recommended to be used in " Kaixin san" and " rehmannia drink".
Acorus/chemistry*
;
Books
;
Drugs, Chinese Herbal
;
Medicine, Chinese Traditional
6.Textual research on Chinese herbaceous peony in Chinese classical prescriptions.
Jia-Chen ZHAO ; Qian-Qian WENG ; Yue ZHANG ; Wei ZHANG ; Hua-Sheng PENG ; Hong-Jun YANG ; Zhi-Lai ZHAN
China Journal of Chinese Materia Medica 2019;44(24):5496-5502
In this paper,the name,origin,producing area,harvesting and processing changes of Paeonia lactiflora used in classical prescriptions were studied by textual research of herbal medicine and field investigation. Chinese herbaceous peony wasn' t distinguished before the Northern and Southern Dynasties; Tao Hongjing proposed that there were two kinds of P. lactiflora in the Northern and Southern Dynasties,but they were not clearly defined; since the Song and Yuan Dynasties,the method of distinguishing P. lactiflora by flower color and root color was proposed. In the Ming Dynasty,people put forward the criteria similar to modern ones,that is,to divide red peony and white peony by means of harvesting and processing,and to continue for future generations. Since modern times,different growth patterns and processing methods have been used to classify red peony and white peony. Paeoniae Radix Alba has gradually formed three major cultivation genuine producing areas: Hangzhou,Sichuan and Bozhou,while Paeoniae Radix Rubra in modern times has praised the wild medicinal materials produced in Inner Mongolia,Toronto and other places. According to textual research,Paeoniae Radix Alba was highly praised in Song Dynasty. When people in Song Dynasty revised the previous literature,they changed " Shaoyao" into " Baishao" and continued to use Paeoniae Radix Alba for future generations. Therefore,the origin of P. lactiflora in classical prescriptions before the Song Dynasty should be determined by the combination of prescription function and prescription meaning evolution; After the Song Dynasty,the origins of " Red Paeonia Root" and " White Paeonia Root" in prescriptions are basically the same as those in today's prescriptions,which should be recorded in ancient prescriptions. For the medicinal flavor of " Paeonia Root" recorded in prescriptions after the Song Dynasty,the origins can be determined by functional domination and the evolution of prescriptions.
China
;
Drugs, Chinese Herbal/history*
;
History, 15th Century
;
History, 16th Century
;
History, 17th Century
;
History, Medieval
;
Humans
;
Paeonia
;
Phytotherapy
;
Plants, Medicinal
7.Textual research on Bupleuri Radix in Chinese classical prescriptions.
Jia-Chen ZHAO ; Qian-Qian WENG ; Yue ZHANG ; Wei ZHANG ; Hua-Sheng PENG ; Hong-Jun YANG ; Zhi-Lai ZHAN
China Journal of Chinese Materia Medica 2020;45(3):697-703
Through consulting the herbs and medical books of past dynasties, combining with modern literature and field investigation, this paper made textual research on the name, origin, producing area, harvesting and processing of Bupleuri Radix used in the Catalogue of Ancient Classical Prescriptions(the first batch).From Han to the Southern and Northern Dynasties, the source of Bupleuri Radix was a mixture of Bupleurum and Peucedanum, it's hard to define the origin of authentic products.In Tang Dynasty, Caryophyllaceae had been used as Bupleuri Radix. In Song Dynasty, it was clear that the genuine production area of Bupleuri Radix was Yinzhou, its origin was B. corzonerifolium and B. yinchowense.After the Ming Dynasty, B. chinense gradually became the mainstream. It has been confirmed that there were differences in the efficacy between Stellaria dichotoma in Caryophyllaceae and Bupleurum in Umbelliferae, however, the use of S. dichotoma is still attributed to Bupleuri Radix. In the Qing Dynasty, S. dichotoma was distinguished from Bupleuri Radix as another medicine. Among the prescriptions containing Bupleuri Radix included in the Catalogue of Classical Prescriptions in Ancient China(the first batch), the mainstream of genuine Bupleuri Radix should be B. scorzonerifolium and B. chinense. It is suggested that the genuine base of Bupleuri Radix should be selected according to the current resources and industrial development of Bupleuri Radix, and it should conform to the Chinese Pharmacopoeia.
Bupleurum/chemistry*
;
China
;
Drugs, Chinese Herbal
;
Medicine, Chinese Traditional
;
Plant Roots/chemistry*
;
Prescriptions